List of Excipients in Branded Drug MOBIC

MOBIC Meloxicam Excipient Strategy and Commercial Opportunities

Last updated: September 25, 2026

MOBIC is the original branded oral meloxicam product, a nonsteroidal anti-inflammatory drug marketed for osteoarthritis and rheumatoid arthritis. Its core composition is now largely commoditized because meloxicam tablets and oral suspensions face extensive generic competition. Commercial opportunity has shifted from basic tablet replication to differentiated excipient systems, pediatric and geriatric delivery, dose flexibility, gastrointestinal tolerability positioning, and reformulations that can support new intellectual property.

The strongest opportunities are oral liquid optimization, orally disintegrating or multiparticulate dosage forms, preservative-free unit doses, and excipient systems that improve dose uniformity and patient adherence. The weakest opportunity is an undifferentiated conventional meloxicam tablet.

What is MOBIC and which meloxicam dosage forms are commercially relevant?

MOBIC contains meloxicam, an oxicam-class NSAID. In the United States, the original product was approved as 7.5 mg and 15 mg tablets and as a 7.5 mg/5 mL oral suspension. The FDA-approved indication is relief of signs and symptoms of osteoarthritis and rheumatoid arthritis in adults. [1]

Product attribute	MOBIC profile
Active ingredient	Meloxicam
Drug class	NSAID; preferential COX-2 inhibitor at therapeutic doses
Original sponsor	Boehringer Ingelheim
Main U.S. dosage forms	7.5 mg and 15 mg tablets; 7.5 mg/5 mL oral suspension
Administration	Once daily
Primary indications	Osteoarthritis and rheumatoid arthritis
Prescription status	Prescription drug
Generic status	Generic meloxicam widely marketed
Key commercial issue	Low differentiation in conventional oral solid dosage forms

MOBIC is not a biologic and does not create biosimilar-specific regulatory risk. Competitive exposure comes from generic meloxicam tablets, capsules in some markets, oral suspensions, and alternative NSAIDs such as celecoxib, naproxen, diclofenac, and ibuprofen.

What excipients are used in MOBIC tablets?

The MOBIC tablet excipient system is a conventional immediate-release formulation designed for manufacturability, content uniformity, mechanical strength, and rapid dissolution.

The U.S. labeling identifies the following tablet excipients:

• Lactose monohydrate
• Microcrystalline cellulose
• Sodium citrate dihydrate
• Povidone
• Crospovidone
• Colloidal silicon dioxide
• Magnesium stearate

The functional roles are straightforward:

Excipient	Primary formulation function
Lactose monohydrate	Diluent and compressibility aid
Microcrystalline cellulose	Filler, binder, and tablet-strength contributor
Sodium citrate dihydrate	Buffering and microenvironment pH control
Povidone	Binder
Crospovidone	Superdisintegrant
Colloidal silicon dioxide	Glidant and flow aid
Magnesium stearate	Lubricant

This composition is commercially familiar and generally accessible to generic manufacturers. It does not create a high barrier to formulation entry. A manufacturer can usually design a bioequivalent meloxicam tablet with a different excipient combination, provided the product meets FDA requirements for pharmaceutical equivalence, bioequivalence, quality, and stability. [1,2]

What excipients are used in MOBIC oral suspension?

The oral suspension is more technically differentiated than the tablet because it must maintain dose uniformity after storage and shaking, prevent rapid sedimentation or hard caking, preserve palatability, and support microbiological stability.

The labeled suspension excipients include:

• Sorbitol
• Microcrystalline cellulose
• Sodium carboxymethylcellulose
• Xanthan gum
• Saccharin sodium
• Citric acid
• Sodium citrate
• Other inactive ingredients identified in the approved labeling

The suspension platform depends on a structured vehicle. Microcrystalline cellulose and sodium carboxymethylcellulose provide suspension structure, while xanthan gum increases viscosity and helps maintain redispersibility. Sorbitol contributes sweetness, bulk, and mouthfeel. Saccharin sodium provides additional sweetness. Citric acid and sodium citrate regulate pH.

The key development risks are:

1. Dose nonuniformity between the first and last administered doses.
2. Sedimentation and failure to redisperse.
3. Excessive viscosity that impairs pouring or oral syringe withdrawal.
4. Chemical degradation during storage.
5. Microbial contamination after opening.
6. Poor taste, especially in pediatric or dysphagia populations.

An optimized commercial suspension can create more value than a standard tablet because caregivers and patients assess the product through practical use, not only through active ingredient equivalence.

What excipient strategy offers the best commercial opportunity for meloxicam?

The highest-value strategy is to match the excipient platform to a defined patient or use-case problem.

Pediatric and dysphagia formulations

Meloxicam is not a broadly established pediatric OTC product, but liquid dosage forms can address adults with dysphagia, patients receiving enteral nutrition, and populations requiring flexible dosing. A modern formulation could use:

• Low-sugar or sugar-free sweetening systems
• Alcohol-free vehicles
• Reduced-viscosity oral suspensions
• Oral syringes with dose markings
• Flavor systems compatible with meloxicam's taste profile
• Preservative systems suitable for multidose packaging
• Unit-dose sachets or cups

The principal opportunity is not simply replacing sorbitol or xanthan gum. It is creating a product with improved redispersibility, low sedimentation, dose accuracy, and better administration through oral syringes or feeding tubes.

Orally disintegrating tablets

An orally disintegrating meloxicam tablet could target patients who have difficulty swallowing conventional tablets. Candidate excipient systems include:

• Mannitol for mouthfeel and rapid dissolution
• Crospovidone or croscarmellose sodium for disintegration
• Low-moisture direct-compression fillers
• Taste-masking polymers
• Flavor and sweetener systems
• Effervescent acid-base pairs, where compatible with stability requirements

The formulation must address meloxicam's low aqueous solubility and taste. Fast disintegration does not automatically produce rapid systemic absorption. The product still requires appropriate dissolution and bioequivalence evidence.

Multiparticulates and sprinkle products

Meloxicam-loaded pellets or granules could be packaged in capsules, sachets, or sprinkle formulations. This approach can provide:

• Flexible dose adjustment
• Better distribution in the gastrointestinal tract
• Easier administration for dysphagia patients
• Modified release potential
• Separation of taste-masking and release-control functions

Multiparticulate systems are more difficult to manufacture and characterize than tablets. They also create opportunities for process patents covering coating, particle-size distribution, release profiles, and dose uniformity.

Fixed-dose combinations

Combination products involving meloxicam and other analgesic or musculoskeletal agents may offer a commercial path, but they face significant clinical and regulatory constraints. Potential concepts include meloxicam with muscle relaxants, gastroprotective agents, or other pain therapies. The formulation challenge is dose scheduling, interaction management, and avoidance of duplicate NSAID exposure.

A combination product would require a clinical and regulatory rationale beyond convenience. Excipients alone would not provide meaningful differentiation.

What patent protection covers MOBIC and meloxicam formulations?

MOBIC's original patent protection has expired in the United States. The commercial opportunity therefore depends on new formulation, manufacturing, packaging, or method-of-use claims rather than the original meloxicam molecule.

The relevant intellectual-property categories are:

Patent category	Commercial relevance
Original meloxicam compound patents	Expired or no longer a practical barrier in major markets
Conventional tablet composition	Low barrier because generic formulations are established
Oral suspension composition	Moderate opportunity if claims cover viscosity, redispersibility, stability, or dose uniformity
Taste-masked multiparticulates	Potentially stronger formulation protection
Modified-release systems	Potentially valuable but clinically and technically demanding
Manufacturing process	Useful where the process materially improves purity, particle size, yield, or stability
Container-closure system	Relevant for preservative-free or moisture-sensitive presentations
Method-of-use claims	Potential opportunity for specific dosing populations or treatment protocols
Combination products	Potentially protectable if supported by clinical benefit

A new formulation patent must avoid merely claiming an obvious substitution of common excipients. Stronger claims would connect the excipient system to a measurable technical result, such as improved redispersibility after accelerated storage, reduced dose variability, improved dissolution under biorelevant conditions, or enhanced chemical stability.

What is the Orange Book status of MOBIC?

The FDA Orange Book historically listed the approved MOBIC products and related patent or exclusivity information. The original patent and regulatory exclusivity periods have expired, and generic meloxicam products are approved in the United States.

The present commercial position is:

• No practical U.S. market exclusivity for conventional MOBIC tablets.
• Extensive ANDA competition for meloxicam tablets.
• Generic competition established for oral suspension products.
• No biosimilar pathway because meloxicam is a small-molecule drug.
• New formulation products would generally require an appropriate 505(b)(2) or abbreviated pathway strategy, depending on the formulation and the extent of change.

A 505(b)(2) strategy may be appropriate for a reformulated meloxicam product that relies partly on FDA findings for an approved meloxicam product but introduces a new dosage form, delivery system, strength, or administration method. The sponsor would need to address drug release, safety, clinical bridging, labeling, and patent certification requirements. [2,3]

When does MOBIC lose exclusivity and what does generic entry mean?

MOBIC lost practical exclusivity when generic meloxicam approvals entered the market. The commercial effect was a sharp reduction in pricing power for standard tablets and increased substitution by pharmacies, hospitals, and managed-care plans.

Generic entry risks remain high for any product that has:

• The same immediate-release tablet dosage form
• The same strengths
• No distinctive patient-use feature
• No meaningful delivery advantage
• No protected manufacturing process
• No differentiated reimbursement position

A reformulated product can still face generic or follow-on competition if the patent claims are narrow, easy to design around, or limited to a small number of excipients. The commercial protection is stronger when the product combines formulation claims with device, packaging, dosing, or method-of-use claims.

Which companies challenge MOBIC and compete with meloxicam?

Generic meloxicam has been marketed by multiple manufacturers, including large generic companies and regional suppliers. Competitive participants have included Teva, Sandoz, Apotex, Dr. Reddy's Laboratories, Lupin, Mylan, and other ANDA holders, depending on the market and product presentation.

The main competitive groups are:

1. Generic meloxicam tablet manufacturers.
2. Generic oral suspension manufacturers.
3. Branded NSAID companies selling celecoxib, naproxen, diclofenac, and ibuprofen.
4. Specialty developers pursuing reformulated or extended-release analgesic products.
5. Compounding pharmacies serving patients needing customized liquid doses.

MOBIC competes on established clinical familiarity, but its brand does not provide a strong barrier against generic substitution. A new meloxicam product must therefore compete through delivery, convenience, tolerability positioning, or channel-specific value.

How strong is the meloxicam patent estate?

The legacy patent estate is weak as a barrier to conventional generic entry because the foundational protection has expired. A new meloxicam patent estate could be stronger if it contains multiple independent claim layers:

• Composition claims covering a defined excipient ratio.
• Performance claims covering dissolution or redispersibility.
• Process claims covering particle-size control or granulation.
• Packaging claims addressing moisture or oxygen exposure.
• Device claims covering oral-syringe administration.
• Method claims covering defined dosing schedules or patient populations.
• Combination claims supported by clinical data.

The strongest formulation patents usually include comparative data against a conventional formulation. Data should demonstrate a technical benefit that is not predictable from the use of routine excipients.

What FDA regulatory strategy applies to a new MOBIC formulation?

A conventional generic tablet would normally use an ANDA pathway. A substantially reformulated or novel dosage form may require a 505(b)(2) application.

Development concept	Likely U.S. regulatory pathway
Conventional 7.5 mg or 15 mg tablet	ANDA
Bioequivalent oral suspension	ANDA if reference product and requirements align
New orally disintegrating tablet	505(b)(2) or ANDA, depending on formulation and reference product
Modified-release meloxicam	Generally 505(b)(2), with additional clinical and pharmacokinetic work
New combination product	505(b)(2) or NDA-type development
Device-assisted liquid product	505(b)(2) or combination-product review, depending on the device

FDA review will focus on pharmaceutical equivalence, bioequivalence, dissolution, dose proportionality, stability, impurities, container closure, microbiological quality, and labeling. Oral suspensions require special attention to in-use stability and dose uniformity.

What commercial opportunities exist for MOBIC excipient innovation?

The most actionable opportunities are listed below.

Opportunity	Value proposition	IP potential	Development risk
Sugar-free oral suspension	Diabetes-friendly and lower-calorie profile	Moderate	Moderate
Preservative-free unit-dose suspension	Improved portability and contamination control	Moderate	Moderate
Oral syringe-compatible suspension	Better dose accuracy and administration	Moderate	Low to moderate
Orally disintegrating tablet	Improved swallowing convenience	Moderate	Moderate
Taste-masked granules	Better adherence and flexible dosing	High	High
Multiparticulate sprinkle product	Dysphagia and dose flexibility	High	High
Modified-release product	Reduced dosing frequency or exposure control	High	High
Moisture-protective packaging	Stability and shelf-life benefits	Moderate	Low to moderate
Low-lactose or lactose-free tablet	Expanded excipient acceptability	Low to moderate	Low
Hospital unit-dose presentation	Workflow and medication-error reduction	Moderate	Low to moderate

The most realistic near-term product is a better oral suspension or an orally disintegrating tablet. Modified release and multiparticulates offer stronger differentiation but require greater clinical and manufacturing investment.

What patent litigation and settlement risks affect meloxicam?

The original MOBIC generic-entry disputes are no longer the main commercial issue because generic competition is established. Future litigation would more likely concern:

• New formulation patents
• ANDA Paragraph IV certifications
• Orange Book listing disputes
• Patent-term calculations
• Regulatory exclusivity for a reformulated product
• Trade-secret claims involving manufacturing processes
• Device and container-closure patents

A Paragraph IV challenge to a new reformulated meloxicam product could trigger Hatch-Waxman litigation and a 30-month stay under applicable conditions. Settlement terms would need review for launch dates, authorized generic rights, supply arrangements, and restrictions on formulation competition. [3]

How does MOBIC compare with competing NSAID products?

Product	Active ingredient	Main differentiation	Generic pressure
MOBIC	Meloxicam	Once-daily NSAID dosing; tablet and suspension history	High
Celebrex	Celecoxib	COX-2 selective profile and capsule platform	High
Naprosyn	Naproxen	Long-established NSAID; multiple generic forms	High
Voltaren	Diclofenac	Multiple topical and oral delivery systems	High
Advil/Motrin	Ibuprofen	Broad OTC access and consumer recognition	Very high

Meloxicam's best commercial position is in once-daily prescription therapy and flexible oral delivery. It does not have a strong basis for premium pricing as a conventional tablet.

Key Takeaways

• MOBIC is an established meloxicam product with expired foundational exclusivity and extensive generic competition.
• The conventional tablet excipient system is readily reproducible and offers limited commercial protection.
• The oral suspension provides greater technical and commercial differentiation because of redispersibility, dose uniformity, palatability, viscosity, and microbiological requirements.
• The strongest near-term opportunities are sugar-free suspensions, preservative-free unit doses, syringe-compatible liquids, and orally disintegrating tablets.
• Multiparticulate and modified-release products may support stronger patents but carry higher development and regulatory risk.
• New patent value should come from demonstrated technical performance, not routine excipient substitution.
• A conventional generic would generally use an ANDA; a meaningfully novel delivery system may require a 505(b)(2) application.
• Meloxicam has no biosimilar risk because it is a small-molecule drug.
• Commercial success depends on patient-use advantages, channel fit, reimbursement, and a layered formulation and manufacturing patent estate.

FAQs About MOBIC Excipient and Formulation Opportunities

Can a lactose-free MOBIC tablet support meaningful differentiation?

A lactose-free tablet may address excipient sensitivity or customer specifications, but the commercial and patent value is usually limited unless paired with improved stability, disintegration, manufacturing efficiency, or a protected dosage form.

Is meloxicam suitable for an oral thin film?

Meloxicam's low aqueous solubility and dose requirements make oral thin-film development challenging. Solubilization, taste masking, film loading, and dose uniformity would determine feasibility.

Can a meloxicam suspension be sold in a preservative-free format?

Yes, but the product would require a suitable container-closure system, microbiological control strategy, in-use stability data, and packaging that limits contamination during administration.

What excipients can improve meloxicam dissolution?

Surfactants, wetting agents, particle-size reduction, amorphous solid dispersions, and selected cyclodextrin systems may improve dissolution. Each approach must be evaluated for stability, safety, manufacturability, and bioequivalence.

Is a new meloxicam formulation eligible for three years of FDA exclusivity?

A qualifying new clinical investigation essential to approval of a new formulation may support three years of regulatory exclusivity under the 505(b)(2) framework. Formulation changes alone do not automatically receive exclusivity. [2]

References

1. U.S. Food and Drug Administration. (2015). Mobic (meloxicam) tablets and oral suspension: Prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process. Center for Drug Evaluation and Research.